Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | PTPN7 | P35236 | 3/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HMGCR | P04035 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7200821 | 0.78 | MCL1 (0.39) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL8945457 | 0.78 | ALDH1A1 (0.32) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL50602 | 0.78 | LMNA (0.40) | CYP2D6CYP2C19ALDH1A1TSHR | |
| SCHEMBL31046 | 0.74 | — | — | |
| SCHEMBL26624539 | 0.73 | MAPT (0.76) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| Succinic Acid SCHEMBL11572701 | 0.73 | CYP2D6 (0.64) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL14516825 | 0.72 | — | — | |
| SCHEMBL2454991 | 0.72 | CYP2D6 (0.56) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL576726 | 0.72 | — | — | |
| SCHEMBL7647153 | 0.70 | PTPN7 (0.55) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2391218-B1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| US-10398781-B2 | Conjugate based systems for controlled drug delivery | SMARTCELLS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180064824-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | MERCK SHARP & DOHME CORP. (US) | 2018-03-08 | — | — | US | disclosed |
| US-9745355-B2 | Binding-site modified lectins and uses thereof | SMARTCELLS, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9579391-B2 | Conjugate based systems for controlled drug delivery | SMARTCELLS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160193351-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS, INC. (US) | 2016-07-07 | — | — | US | disclosed |
| US-9265838-B2 | Conjugate based systems for controlled drug delivery | SMART CELLS, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150265717-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS, INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-9068013-B2 | Recombinant lectins, binding-site modified lectins and uses thereof | SMART CELLS, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9050370-B2 | Conjugate based systems for controlled drug delivery | SMARTCELLS, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| EP-2408470-A1 | Soluble non-depot insulin conjugates and uses thereof | Smartcells, Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20120010134-A1 | SOLUBLE NON-DEPOT INSULIN CONJUGATES AND USES THEREOF | SMARTCELLS, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20110301083-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS, INC. | 2011-12-08 | — | — | US | disclosed |
| EP-2391215-A1 | BINDING-SITE MODIFIED LECTINS AND USES THEREOF | Smartcells, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20110281792-A1 | BINDING-SITE MODIFIED LECTINS AND USES THEREOF | SMARTCELLS, INC. | 2011-11-17 | — | — | US | disclosed |
| US-20110275560-A1 | SYNTHETIC CONJUGATES AND USES THEREOF | SMARTCELLS, INC. | 2011-11-10 | — | — | US | disclosed |
| WO-2010107520-A1 | SOLUBLE NON-DEPOT INSULIN CONJUGATES AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010088286-A1 | SYNTHETIC CONJUGATES AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010088261-A1 | BINDING-SITE MODIFIED LECTINS AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010088294-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275560-A1 | SYNTHETIC CONJUGATES AND USES THEREOF | SLC2A4, SLC2A8, CD44 | CYP1A2 4726/4885CYP2D6 3735/4885MAPT 3495/4885 |
| US-10398781-B2 | Conjugate based systems for controlled drug delivery | SI, CSGALNACT1, CD44 | CYP1A2 701/4885CYP2D6 292/4885MAPT 2050/4885 |
| US-20120010134-A1 | SOLUBLE NON-DEPOT INSULIN CONJUGATES AND USES THEREOF | GPR119, IAPP, IRS1 | CYP1A2 4210/4885CYP2D6 3388/4885MAPT 3646/4885 |
| US-20110301083-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SI, CSGALNACT1, CD44 | CYP1A2 701/4885CYP2D6 292/4885MAPT 2050/4885 |
| US-20110281792-A1 | BINDING-SITE MODIFIED LECTINS AND USES THEREOF | SIGLEC7, SIGLEC9, LGALS3BP | CYP1A2 4317/4885CYP2D6 2605/4885MAPT 4266/4885 |
| US-20180064824-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SI, CSGALNACT1, CD44 | CYP1A2 701/4885CYP2D6 292/4885MAPT 2050/4885 |
| US-20160193351-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SI, CSGALNACT1, CD44 | CYP1A2 701/4885CYP2D6 292/4885MAPT 2050/4885 |
| US-20150265717-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SI, CSGALNACT1, CD44 | CYP1A2 701/4885CYP2D6 292/4885MAPT 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.